Economic Burden Associated with Pulmonary Arterial Hypertension in the United States: Economic Burden Associated With Pulmonary Arterial Hypertension in the United States: A. Watzker et al.

Watzker, Anna; Alsumali, Adnan; Ferro, Christine; Dieguez, Gabriela; Park, Clare; Lautsch, Dominik; El-Kersh, Karim

Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pressure in the pulmonary arteries, commonly resulting in right heart failure. PAH is associated with a high economic burden throughout the duration of the disease. Methods: This retrospective cohort study of the Milliman Contributor Health Source Data, the Medicare 100% Research Identifiable Files, and the Merative Marketscan® Commercial dataset between 2018 and 2020 identified adult patients with prevalent PAH based on the earliest qualifying diagnosis date or medication date ('index date') between January 1, 2019 and November 30, 2020. Outcomes were assessed using patient data from index date through the earliest of end of enrollment, end of data, or death (Medicare fee-for-service [FFS] only). All-cause and PAH-related medical and pharmacy costs per-patient per-month (PPPM) and healthcare resource utilization per 1000 patients were summarized. Results: The study included 11,670 Medicare FFS, 1021 Medicare Advantage, 274 Medicaid, and 1174 commercially insured patients in the US. The annual national burden to payers was estimated to be US$3.1 billion. The PPPM payer costs ranged from US$6500 to US$14,742; out-of-pocket (OOP) costs ranged from US$341 to US$907 PPPM. Inpatient utilization rate ranged from 435 to 770 per 1000 patients for all-cause admissions and from 15 to 58 per 1000 patients for PAH-related admissions. Conclusions: This study demonstrates that PAH continues to be associated with a high economic burden and healthcare resource utilization across all payer types within the US healthcare system.

PULMONARY arterial hypertension; MEDICARE Part C; MEDICAL care costs; MEDICAL sciences; HOSPITAL admission & discharge

PharmacoEconomics, 2025, Vol 43, Issue 1, p83

1170-7690

Academic Journal

10.1007/s40273-024-01427-2